The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells
Sign Up to like & getrecommendations! Published in 2019 at "Cellular Oncology"
DOI: 10.1007/s13402-019-00443-1
Abstract: PurposeAlthough EGFR activation is a hallmark of glioblastoma (GBM), anti-EGFR therapy has so far not yielded the desired effects. Targeting PI3K/Akt has been proposed as a strategy to increase the cellular sensitivity to EGFR inhibitors.… read more here.
Keywords: response; gbm; foxo3a; egfr inhibition ... See more keywords
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids.
Sign Up to like & getrecommendations! Published in 2021 at "Nature communications"
DOI: 10.1038/s41467-021-27276-7
Abstract: Inhibition of RTK pathways in cancer triggers an adaptive response that promotes therapeutic resistance. Because the adaptive response is multifaceted, the optimal approach to blunting it remains undetermined. TNF upregulation is a biologically significant response… read more here.
Keywords: inhibition; resistance; egfr inhibition; inhibition rtk ... See more keywords
Discovery of Rhodanine and Thiazolidinediones as Novel Scaffolds for EGFR Inhibition: Design, Synthesis, Analysis and CoMSIA Studies
Sign Up to like & getrecommendations! Published in 2020 at "Polycyclic Aromatic Compounds"
DOI: 10.1080/10406638.2020.1836004
Abstract: This study reports, 35 novel rhodanine, its bioisosteres thiazolidinediones and is tested for EGFR inhibition. These molecules are designed by using a pharmacophore-based superimpose approach takin... read more here.
Keywords: egfr inhibition; inhibition; thiazolidinediones novel; novel scaffolds ... See more keywords
EGFR inhibition in EGFR‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15701
Abstract: Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR‐mutant non–small‐cell lung cancer (NSCLC) cells. However, little is known about the mechanisms through which these drugs alter the tumor phenotype… read more here.
Keywords: egfr mutant; egfr inhibition; egfr; tumor ... See more keywords
ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells
Sign Up to like & getrecommendations! Published in 2020 at "Science Signaling"
DOI: 10.1126/scisignal.abb9820
Abstract: Blocking the antiapoptotic protein Mcl-1 sensitizes TNBC cells to erlotinib. Unmasking drug sensitivity Although the activity of the epidermal growth factor receptor (EGFR) pathway is increased in triple-negative breast cancers (TNBC), patients are generally insensitive… read more here.
Keywords: egfr; negative breast; egfr inhibition; cancer ... See more keywords
The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-3725
Abstract: Purpose: Cholangiocarcinoma (CCA) is a desmoplastic tumor of the biliary tree in which epidermal growth factor receptor (EGFR) is overexpressed and contributes to cancer progression. Although EGFR has been envisaged as a target for therapy,… read more here.
Keywords: egfr inhibition; cca; cancer; growth ... See more keywords
EGFR inhibition leads to enhanced desmosome assembly and cardiomyocyte cohesion via ROCK activation
Sign Up to like & getrecommendations! Published in 2023 at "JCI Insight"
DOI: 10.1172/jci.insight.163763
Abstract: Arrhythmogenic cardiomyopathy (AC) is a familial heart disease partly caused by impaired desmosome turnover. Thus, stabilization of desmosome integrity may provide new treatment options. Desmosomes, apart from cellular cohesion, provide the structural framework of a… read more here.
Keywords: desmosome assembly; inhibition; rock; cohesion ... See more keywords
EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14163943
Abstract: Simple Summary Lung cancer that is driven by mutations in the epidermal growth factor receptor (EGFR) is currently treated with tyrosine kinase inhibitors (TKIs). Although patients initially respond well to TKI treatment, drug resistance against… read more here.
Keywords: egfr driven; egfr inhibition; egfr; immune ... See more keywords
Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23169014
Abstract: Head and neck squamous cell carcinomas (HNSCCs) are a type of cancer originating in the mucosal epithelium of the mouth, pharynx, and larynx, the sixth most common cancer in the world. However, there is no… read more here.
Keywords: cell; carcinoma cells; egfr inhibition; treatment ... See more keywords
EGFR deficiency leads to impaired self-renewal and pluripotency of mouse embryonic stem cells
Sign Up to like & getrecommendations! Published in 2019 at "PeerJ"
DOI: 10.7717/peerj.6314
Abstract: Background Self-renewal and pluripotency are considered as unwavering features of embryonic stem cells (ESCs). How ESCs regulate the self-renewal and differentiation is a central question in development and regenerative medicine research. Epidermal growth factor receptor… read more here.
Keywords: egfr inhibition; renewal pluripotency; pluripotency; self renewal ... See more keywords